Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kymera Therapeutics (KYMR – Research Report) and S...

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and SurModics (SRDX)

In a report released yesterday, Mayank Mamtani from B. Riley Securities maintained a Buy rating on Kymera Therapeutics, with a price target of $80....

B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Kymera Therapeutics today. The company’s shares closed yesterday at $59.91...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KYMR	$66.04	+2.18%	768.95K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KYMR	$66.04	+2.2%	768.95K
3
4
5
6

KYMR

KYMR

Get Kymera Therapeutics Inc. Data in Excel

Get Kymera Therapeutics Inc. Data in Excel